Xenon Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

• Xenon Pharmaceuticals Inc XENE.OQ reported a quarterly adjusted loss of $1.15​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -81 cents. The mean expectation of nineteen analysts for the quarter was for a loss of $1.15 per share. Wall Street expected results to range from $-1.27 to -99 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Xenon Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.31​.

• The company reported a quarterly loss of $105.26 million.

• Xenon Pharmaceuticals Inc shares had fallen by 0.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Xenon Pharmaceuticals Inc is $55.00, about 19% above its last closing price of $44.58

This summary was machine generated from LSEG data February 26 at 10:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)